Return on Equity (ROE)
since 2012
Calculation
AbbVie Inc., ROE, long-term trends, calculation
| ROE | = | 100 | × | Net earnings attributable to AbbVie Inc.1 | ÷ | Stockholders’ equity (deficit)1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | 46.94% | = | 100 | × | 4,863) | ÷ | 10,360) |
| Dec 31, 2022 | 68.60% | = | 100 | × | 11,836) | ÷ | 17,254) |
| Dec 31, 2021 | 74.91% | = | 100 | × | 11,542) | ÷ | 15,408) |
| Dec 31, 2020 | 35.30% | = | 100 | × | 4,616) | ÷ | 13,076) |
| Dec 31, 2019 | — | = | 100 | × | 7,882) | ÷ | (8,172) |
| Dec 31, 2018 | — | = | 100 | × | 5,687) | ÷ | (8,446) |
| Dec 31, 2017 | 104.16% | = | 100 | × | 5,309) | ÷ | 5,097) |
| Dec 31, 2016 | 128.41% | = | 100 | × | 5,953) | ÷ | 4,636) |
| Dec 31, 2015 | 130.39% | = | 100 | × | 5,144) | ÷ | 3,945) |
| Dec 31, 2014 | 101.84% | = | 100 | × | 1,774) | ÷ | 1,742) |
| Dec 31, 2013 | 91.90% | = | 100 | × | 4,128) | ÷ | 4,492) |
| Dec 31, 2012 | 156.85% | = | 100 | × | 5,275) | ÷ | 3,363) |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
Comparison to Competitors
AbbVie Inc., ROE, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | 46.94% | 107.78% | 27.27% | 8.91% | 48.65% | 24.81% | 51.11% | 0.97% | -34.03% | 2.38% | 15.22% | 12.83% |
| Dec 31, 2022 | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 21.62% | 23.36% | 31.57% | 43.73% | 32.79% | 19.14% | 15.80% |
| Dec 31, 2021 | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 29.55% | 28.20% | 34.17% | 86.26% | 28.47% | 43.03% | 18.94% |
| Dec 31, 2020 | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 0.68% | 23.25% | 27.91% | -29.17% | 15.21% | 31.86% | 18.47% |
| Dec 31, 2019 | — | 81.07% | 6.66% | 9.94% | 319.09% | 23.91% | 25.42% | 37.99% | -43.75% | 25.77% | 19.08% | 12.45% |
| Dec 31, 2018 | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.51% | 25.60% | 23.30% | -25.14% | 17.59% | 27.91% | 10.65% |
| Dec 31, 2017 | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 22.64% | 2.16% | 6.97% | — | 29.47% | 19.51% | 8.76% |
| Dec 31, 2016 | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 71.48% | 23.49% | 9.78% | — | 12.12% | 20.13% | 9.39% |
| Dec 31, 2015 | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 97.70% | 21.66% | 9.94% | — | 10.75% | 17.40% | 9.25% |
| Dec 31, 2014 | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 78.45% | 23.40% | 24.50% | — | 12.81% | 13.69% | 9.22% |
| Dec 31, 2013 | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 27.05% | 18.68% | 8.85% | — | 28.83% | 21.74% | 7.55% |
| Dec 31, 2012 | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 27.84% | 16.74% | 11.63% | — | 17.93% | 60.24% | 7.62% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | 46.94% | 18.83% |
| Dec 31, 2022 | 68.60% | 28.81% |
| Dec 31, 2021 | 74.91% | 31.93% |
| Dec 31, 2020 | 35.30% | 16.48% |
| Dec 31, 2019 | — | 27.56% |
| Dec 31, 2018 | — | 25.64% |
| Dec 31, 2017 | 104.16% | 14.60% |
| Dec 31, 2016 | 128.41% | 22.31% |
| Dec 31, 2015 | 130.39% | 21.69% |
| Dec 31, 2014 | 101.84% | 21.22% |
| Dec 31, 2013 | 91.90% | 20.56% |
| Dec 31, 2012 | 156.85% | 18.37% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., ROE, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | 46.94% | 17.03% |
| Dec 31, 2022 | 68.60% | 22.88% |
| Dec 31, 2021 | 74.91% | 24.08% |
| Dec 31, 2020 | 35.30% | 15.82% |
| Dec 31, 2019 | — | 20.90% |
| Dec 31, 2018 | — | 17.33% |
| Dec 31, 2017 | 104.16% | 14.32% |
| Dec 31, 2016 | 128.41% | 17.89% |
| Dec 31, 2015 | 130.39% | 18.18% |
| Dec 31, 2014 | 101.84% | 18.66% |
| Dec 31, 2013 | 91.90% | 18.20% |
| Dec 31, 2012 | 156.85% | 17.48% |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).